Teriparatide: Research & Studies

Research Overview#

Teriparatide has the most extensive and long-standing evidence base of any osteoanabolic agent, with over 20 years of clinical experience since its FDA approval in 2002. The evidence encompasses the landmark Fracture Prevention Trial (Neer et al., 2001), the glucocorticoid-induced osteoporosis trial (Saag et al., 2007), an 18-year post-marketing osteosarcoma surveillance program, and numerous studies of sequential therapy strategies.

The evidence level is classified as high based on multiple randomized controlled trials, active-comparator data, FDA approval for three indications, and the most extensive long-term safety data of any osteoanabolic agent.

Fracture Prevention Trial (Pivotal Study)#

Study Design#

The Fracture Prevention Trial (Neer et al., 2001; PMID 11346808) was a randomized, double-blind, placebo-controlled trial enrolling 1,637 postmenopausal women with at least one prior vertebral fracture. Participants were randomized to teriparatide 20 mcg, teriparatide 40 mcg, or placebo administered daily by subcutaneous injection.

The trial was originally planned for 36 months but was terminated early after a median follow-up of 21 months due to the discovery of osteosarcoma in long-term rat carcinogenicity studies. Despite the shortened duration, statistically significant fracture reduction was achieved.

Key Results#

Teriparatide 20 mcg daily demonstrated robust fracture reduction:

• Vertebral fractures: 65% risk reduction (RR 0.35, 95% CI 0.22-0.55)
• Nonvertebral fractures: 53% risk reduction (RR 0.47, 95% CI 0.25-0.88)
• Moderate-to-severe vertebral fractures: Approximately 90% risk reduction
• Lumbar spine BMD: +9% at 21 months
• Femoral neck BMD: +3% at 21 months
• Total body bone mineral: Significant increase

The 40 mcg dose provided similar fracture reduction but with higher adverse event rates, supporting the selection of 20 mcg as the approved dose.

Significance#

The Fracture Prevention Trial established the concept of osteoanabolic therapy -- building new bone rather than merely slowing bone loss. The magnitude of fracture reduction exceeded that of bisphosphonates available at the time and opened a new therapeutic paradigm.

Glucocorticoid-Induced Osteoporosis Trial#

Study Design#

The GIO trial (Saag et al., 2007; PMID 18003959) was an 18-month randomized, double-blind, double-dummy trial comparing teriparatide 20 mcg SC daily with alendronate 10 mg orally daily in 428 patients (73% women) receiving chronic glucocorticoids (prednisone equivalent >=5 mg daily for at least 3 months).

Key Results#

Teriparatide demonstrated clear superiority over alendronate:

• Lumbar spine BMD: +7.2% (teriparatide) vs +3.4% (alendronate), P<0.001
• Total hip BMD: Significantly greater increase with teriparatide
• Vertebral fractures: 0.6% (teriparatide) vs 6.1% (alendronate), P=0.004
• Nonvertebral fractures: 5.6% vs 3.7% (not significantly different)

This trial was pivotal for the FDA approval of teriparatide for GIO and established that anabolic therapy is more effective than antiresorptive therapy in this high-risk population where ongoing glucocorticoids suppress bone formation.

VERO Trial: Teriparatide vs. Risedronate#

The VERO trial (Kendler et al., 2018) directly compared teriparatide 20 mcg SC daily to risedronate 35 mg weekly orally in 1,360 postmenopausal women with severe osteoporosis over 24 months. Teriparatide was associated with significantly lower risk of new vertebral fractures (5.4% vs 12.0%, RR 0.44, P<0.0001) and clinical fractures. This was the first trial to demonstrate superiority of an osteoanabolic agent over an antiresorptive for fracture reduction as the primary endpoint.

Osteosarcoma Post-Marketing Surveillance#

Background#

The early termination of the Fracture Prevention Trial in 2001 was triggered by the observation of osteosarcoma in Fischer 344 rats treated with high-dose teriparatide for near-lifetime durations. This led to the initial boxed warning and 2-year treatment limitation.

18-Year Surveillance Results#

Eli Lilly conducted a mandated post-marketing surveillance study linking commercial pharmacy data to state cancer registries to detect any increased osteosarcoma incidence among teriparatide users. After 18 years of surveillance:

• No increase in osteosarcoma incidence was detected among teriparatide users
• The observed osteosarcoma rate in teriparatide users was consistent with background population rates
• Human bone biology (osteonal remodeling, non-continuous growth) fundamentally differs from rat bone biology

Based on these results, the FDA removed the osteosarcoma boxed warning and the 2-year treatment duration limitation in November 2020.

Sequential Therapy Evidence#

Multiple studies have examined the optimal approach after teriparatide discontinuation:

• Teriparatide followed by alendronate: BMD gains are preserved and modestly extended at the spine; hip BMD is maintained
• Teriparatide followed by denosumab: Greater BMD consolidation than with bisphosphonates; denosumab may be the preferred sequential agent
• Teriparatide followed by zoledronic acid: Single annual infusion provides convenient consolidation

The consistent finding across studies is that antiresorptive consolidation is essential -- BMD declines rapidly (within 12 months) if no subsequent therapy is provided.

Evidence Quality Assessment#

Key Research Gaps#

1. Optimal duration beyond 2 years: With the boxed warning removed, the optimal duration of anabolic therapy before transitioning to antiresorptive is uncertain.

2. Comparison with romosozumab: No head-to-head trial with romosozumab (anti-sclerostin antibody). Both are osteoanabolic options for high-risk patients.

3. Sequential therapy optimization: The best antiresorptive agent and timing for consolidation after teriparatide remains an active area of investigation.

4. Combination therapy: Whether concurrent teriparatide + denosumab provides additive benefit over sequential use (limited data suggest potential additive effects on BMD).

5. Re-treatment: Safety and efficacy of a second course of teriparatide after a period of antiresorptive therapy has limited data.

Related Reading#

• Teriparatide overview and research guide
• Teriparatide dosing protocols
• Teriparatide molecular structure